Patent · US Active

Formulations of enzalutamide

US11839689B2 · kind B2 · utility

0Cited by

6References

7Claims

0Family size

Assignees

ASTELLAS PHARMA INC. · JP
Medivation Prostate Therapeutics LLC · US

Inventors

Douglas Alan Lorenz · Bend, US
Sanjay Konagurthu · Bend, US
Randy J. Wald · Bend, US
Jason A. Everett · Bend, US
Sheila Matz · North Conway, US
Yuuki Takaishi · Tokyo, JP
Toshiro Sakai · Tokyo, JP
Ryousuke Irie · Tokyo, JP
Shinsuke Oba · Oshima, JP
Hiroyasu Toyota · Tokyo, JP
Koji Nishimura · Tokyo, JP
Atsushi Kanbayashi · Tokyo, JP

Key dates

Filing date	Nov 11, 2022
Grant date	Dec 12, 2023
Priority date	—
Expiry date	Nov 11, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D233/86
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.